Other Events ·
BioCryst Pharmaceuticals is amending its June 29, 2026 filing to disclose estimated costs associated with…
BCRXBiocryst Pharmaceuticals Inc
BioCryst Pharmaceuticals is amending its June 29, 2026 filing to disclose estimated costs associated with discontinuing internal discovery programs and closing its Birmingham, Alabama Discovery Center of Excellence. The company estimates one-time expenses between $6.2 million and $7.5 million for employee termination benefits and severance, with approximately $5.3 million to $6.6 million expected in cash expenditures. Total facility closure costs remain unestimated as management analysis is ongoing. BioCryst Pharmaceuticals operates in the biotechnology industry, focusing on developing treatments for rare diseases.